Oxford Events, the new replacement for OxTalks, will launch on 16th March. From now until the launch of Oxford Events, new events cannot be published or edited on OxTalks while all existing records are migrated to the new platform. The existing OxTalks site will remain available to view during this period.
From 16th, Oxford Events will launch on a new website: events.ox.ac.uk, and event submissions will resume. You will need a Halo login to submit events. Full details are available on the Staff Gateway.
30 years of research has highlighted the crucial role of oestrogen in the disease profile of women with psychotic disorders. However, we have not translated this knowledge into tailored treatment strategies. I will present the work conducted during my PhD, which focused on understanding the impact of sex and sex hormones, particularly oestrogen, on the disease trajectory and treatment of psychotic disorders. In the first part, I will explore the interplay between sex, oestrogen, and current treatment strategies for psychosis, emphasising the links between hyperprolactinaemia and clinical outcomes, as well as the influence of sex on the effectiveness and tolerability of antipsychotics. In the second part, I will discuss how we might harness the beneficial effects of oestrogen to optimise treatment strategies, drawing on evidence from clinical trials and birth cohort studies. Lastly, I will provide a brief overview of our current efforts to better understand the impact of sex and sex hormones on the disease course of schizophrenia-spectrum disorders, with the aim of advancing care.
This seminar is hosted in person and online, to join via Zoom, please use the details below:
zoom.us/j/93598736019?pwd=tHJ65nmXIrmYTUhi7YRbbdlnyi5Ie6.1
Meeting ID: 935 9873 6019
Passcode: 897963
